IBA to share long-term growth strategy at upcoming 2025 Capital Markets Day Louvain-la-Neuve, Belgium, 04 April, 2025 – (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, will be hosting a Capital Markets Day (CMD) this coming Monday 7 April from 2pm to 5:00pm CEST (8am ET to 11:00am ET) at its headquarters in Louvain-la-Neuve, Belgium, and via live webcast. At the event IBA’s management team will outline the company’s strategic roadmap and long-term growth ambitions. The agenda is outlined below: Webcast open: 2pmPurpose, Vision & StrategyBu...
IBA présente sa stratégie de croissance à long terme lors de son Capital Markets Day 2025 Louvain-la-Neuve, Belgique, le 4 avril 2025 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules, organise un Capital Markets Day (CMD-journée investisseurs) ce lundi 7 avril de 14h à 17h00 heure de Bruxelles (8h à 11h00 heure de Washington) à son siège à Louvain-la-Neuve et via un webcast. Lors de cet événement, la direction de la société présentera la feuille de route stratégique de l'entreprise et ses ambitions de croissance à long terme. L...
HEADLINES: • LPP: mediocre 4Q24 – EBIT 4-5% below expectations, but decent start to the year; FY25E guidance broadly maintained, and FY26-27E guidance of stable margins, despite major sales growth acceleration POSITIVE • EEMEA macro: US reciprocal tariff effects • Trade Estates: strong 2024 results POSITIVE • Motor Oil Hellas: 4Q24 results – CCS EBITDA in line with the consensus, but net income weak NEUTRAL • Eurocash: 4Q24 in line with the prelims NEUTRAL • Text: 4Q24-25 (calendar 1Q25) prelimi...
In this April 2025 update of the KBC Securities' Dynamic Top Pick List, we are removing Gimv and adding Adyen. Since adding Gimv to the Dynamic Top Pick List in mid-December 2024, Gimv's performance has remained flat. However, month-to-date, it has increased by nearly 7%, while the indices have all declined. Given the backdrop of a tariff war brewing, we think it's time to remove Gimv from the Dynamic Top Pick List as medium-sized businesses are more likely to feel the pinch of lower demand and...
Weekly share repurchase program transaction details Amsterdam, April 2, 2025 SBM Offshore reports the transaction details related to its EUR130 million (c. US$140 million) share repurchase program for the period March 27, 2025 through April 2, 2025. The repurchases were made under the EUR65 million share repurchase program announced on February 29, 2024, effective from March 1, 2024 and increased by EUR65 million as announced on August 8, 2024. The objective of the program is to reduce share capital and, in addition, to provide shares for regular management and employee share programs. In...
EME Equity Market – March 2025 Türkiye hammered, once again. The MSCI EM Europe Index advanced 0.5% in EUR terms and 4.5% mom in USD terms in March. The Czech PX Index was the best performer (+7.0% mom in EUR terms), followed by the Greek ASE (+4.8% mom), Polish WIG (+3.7% mom) and Hungarian BUX(+1.3% mom) indices (all in EUR terms). There was a muted performance from the Romanian BET Index (-0.1% mom in EUR terms). The Turkish ISE30 finished in the red again, declining 9.5% mom in EUR terms.
IBA signs contract for a Proteus®ONE solution to be installed at the Tri-Service General Hospital in Taiwan Louvain-La-Neuve, Belgium, April 2nd, 2025 – (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a contract for the supply of a Proteus®ONE1 compact proton therapy solution to be located at the Tri-Service General Hospital in Taipei, Taiwan. The contract includes the supply of a Proteus®ONE system and a Quality Assurance...
IBA signe un contrat pour installer une solution Proteus®ONE au Tri-Service General Hospital à Taïwan Louvain-la-Neuve, Belgique, le 2 avril 2025 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour le traitement du cancer, annonce aujourd'hui la signature d'un contrat pour la fourniture d'une solution compacte de protonthérapie Proteus®ONE1 au Tri-Service General Hospital à Taipei, Taïwan. Le contrat comprend la fourniture d'un système Proteus®ONE et d'un package d'ass...
HEADLINES: • Athens Exchange Group: bottom-line miss in 4Q24, on higher costs, but proposed DPS in line with expectations NEUTRAL • AROBS Transilvania Software: publishes its 2025 budget POSITIVE • MedLife: publishes its 2025 budget NEGATIVE • CCC: new financing agreement, extending factoring line POSITIVE • DataWalk: sale to Coöperatieve Rabobank; total contract value reaches PLN 66.1m POSITIVE • Orlen: 2024 consolidated results to be affected by one-offs NEUTRAL • Poland macro: preliminary Mar...
IBA – ACQUISITION OF OWN SHARES Immediate Release – March 31st, 2025 Louvain-la-Neuve, Belgium, March 31st, 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on March 24th, 2025. Under this program, IBA has requested a financial intermediary to repurchase up to 650,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until December 31st, 2025, effective as from Marc...
IBA – ACQUISITION D’ACTIONS PROPRES Publication immédiate – 31 mars 2025 Louvain-la-Neuve, Belgique, 31 mars 2025 - Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique par la présente certaines informations relatives à son programme de rachat d'actions annoncé le 24 mars 2025. Dans le cadre de ce programme, IBA a demandé à un intermédiaire financier de racheter en son nom un maximum de 650.000 actions ordinaires IBA selon les termes d'un mandat valable jusqu'au 31 décem...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.